

A Clinical Trial in Small Cell Lung Cancer (SCLC)

For patients with Extensive-stage SCLC who can receive a platinum-based chemotherapy regimen and a PD-L1-based regimen


BMS Study: CA245-0001/TIGOS



www.BMS-SCLCTrials.com



About This Clinical Trial



You may be eligible to join the TIGOS Trial if you are at least 18 years of age and:

- ✓ You have been diagnosed with extensive-stage SCLC.
- ✓ You have not received prior treatment.
- ✓ Imaging has shown at least one tumor outside of the central nervous system.
- ✓ You can receive a platinum-based chemotherapy regimen and a PD-L1-based regimen.

Clinical trials have strict rules to protect participants and ensure reliable results. Your doctor can help you determine if you're eligible and if the trial is right for you by reviewing your health history and the requirements.

What is the TIGOS Clinical Trial?

TIGOS is Phase 3 clinical trial for people with extensive-stage SCLC. This means the cancer has spread to other parts of the body outside of the lungs.

Participants will be randomly assigned¹ to receive either the trial drug (BMS-986489) in combination with chemotherapy or atezolizumab in combination with chemotherapy.

Participation is completely voluntary. Your privacy will be maintained during and after the study. Requesting information about this research study does not obligate you to take part in it.

People who take part in clinical studies are key to advancing medical research. By taking part in the TIGOS study, you will be aiding medical research which may help others with SCLC in the future. Over the course of the study, a participant's health may get better, get worse, or stay the same.

People who are considering taking part in the study will be given a list of risks and possible discomforts before agreeing to participate. As with any medication, there may be a reaction to the study drug.

¹ Randomization means participants are assigned to treatment groups by chance, ensuring fairness and unbiased results. This helps compare the effectiveness and safety of different treatments.

For Physicians

To discuss a potential patient referral, please contact your nearest Principal Investigator or site staff to learn more.

